Cancer Symptom Science is the first interdisciplinary compilation of research on the mechanisms underlying the expression of cancer-related symptoms. It presents innovations in clinical, animal and in vitro research, research methods in brain imaging, and statistical-descriptive approaches to understanding the mechanistic basis of symptom expression. This volume also provides perspectives from patients, government and industry. By collecting and synthesizing the developing threads of new approaches to understanding cancer-related symptoms, the book promotes a pioneering framework for merging behavioral and biological disciplines to clarify mechanisms of symptom evolution, incorporating new technologies, testing novel agents for symptom control, and improving patient functioning and quality of life both during and after cancer treatment. With an expert editorial team led by Charles S. Cleeland, an internationally-recognized leader in cancer pain assessment and treatment, this is essential reading for surgical, clinical and medical oncologists, academic researchers, and pharmaceutical companies developing new agents to control symptom expression.

Cancer Symptom Science is the first interdisciplinary compilation of research on the mechanisms underlying the expression of cancer-related symptoms. It presents innovations in clinical, animal and in vitro research, research methods in brain imaging, and statistical-descriptive approaches to understanding the mechanistic basis of symptom expression. This volume also provides perspectives from patients, government and industry. By collecting and synthesizing the developing threads of new approaches to understanding cancer-related symptoms, the book promotes a pioneering framework for merging behavioral and biological disciplines to clarify mechanisms of symptom evolution, incorporating new technologies, testing novel agents for symptom control, and improving patient functioning and quality of life both during and after cancer treatment. With an expert editorial team led by Charles S. Cleeland, an internationally-recognized leader in cancer pain assessment and treatment, this is essential reading for surgical, clinical and medical oncologists, academic researchers, and pharmaceutical companies developing new agents to control symptom expression.

This book presents the current state of the nursing science in topics relevant to the care of pediatric oncology patients and their families across the treatment trajectory and is framed within a precision health framework. The spectrum of topics covered is wide, including, for example, symptom management, self-care management, exercise and physical activity, family-centered care, palliative care, the role of the nurse in treatment decision making, patient and nurse resiliency, survivorship, and genetic counseling. Throughout, there is a focus on the implications of research for nursing practice, highlighting which elements of the available evidence are ready for translation into practice and which are not. In addition, careful attention is paid to the role that nursing can play in further advancing science through clinical research. The authors are leading experts from across the globe. The book will be of special interest for pediatric oncology nurses, including direct care nurses, research nurses, and nursing leaders, and will also be a stimulating source for researchers and non-oncology nurses.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

Accompanying CD-ROM contains customizable patient self-care guides.

The past few years have seen tremendous strides in our understanding of cancer, including new hypotheses about its genetic origins and new treatment alternatives using the body’s own immune response. In this eBook, The Science of Cancer, we examine what we know and what we’re finding out about this scourge of humankind. We delve into the molecular basis and complex causes of cancer, the arguments for and against screenings, new and targeted therapies, and minimizing risk. In “How Cancer Arises,” Robert Weinberg presents what has been the central dogma of cancer genetics, which says that a handful of essential mutations in specific genes lead to tumor growth; however, recent discoveries are challenging this theory, as we see in “Untangling the Roots of Cancer” and “Stem Cells: The Real Culprits in Cancer?” Early detection of cancer is important for treatment, but not all screening tests are created equal. In “The Great Prostate Cancer Debate,” Mark Garnick lays out the controversy over the value of the prostate-specific antigen test for prostate cancer and the rationale against screening. With our increasing knowledge of cancer’s causes, exciting targeted therapies are on the rise, including homing in on stem cells, making use of viruses, and manipulating the immune system as we see in “A New Ally against Cancer,” which focuses on treatment with therapeutic vaccines. Does this mean a cure is around the corner? Perhaps not, according to Scientific American Editor Dina Fine Maron in “Can We Truly ‘Cure’ Cancer?” But with remission rates rising for certain types of cancers and with new discoveries opening up further avenues of research, there is reason for optimism.